FibroBiologics, Inc. Common StockFBLGNASDAQ
Loading
SG&A Expense Growth Under PressureDecelerating
Percentile Rank20
3Y CAGR-92.3%
Year-over-Year Change
Year-over-year SG&A expense growth
3Y CAGR
-92.3%/yr
Annual compound
Percentile
P20
Within normal range
vs 3Y Ago
0x
Contraction
Streak
3 yr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| 2025 | 0.10% |
| 2024 | 41.59% |
| 2023 | 96.42% |
| 2022 | 214.10% |
| 2021 | 111.40% |
| 2020 | 0.00% |